Maxygen has agreed to transfer a portfolio of preclinical dengue antigens to Sanofi Pasteur for use developing a second generation vaccine. Maxygen stands to gain up to $24.5 million in the deal. The dengue virus afflicts more than 50 million people worldwide. About a week ago Maxygen announced that it is closing its facility in Denmark [1] in a cost-cutting move.
- check out the release [2] on the deal
- here's the AP report [3] on Maxygen
ALSO: Take a look at Sanofi's pipeline. Report [4]
Related Articles:
New tech drives huge growth in vaccine business. Report [5]
New approach to vaccine development. Report [6]
Vaccine "renaissance" attracts huge new venture investments. Report [7]
Roche drops out of dev deal with Maxygen. Report [8]
Links:
[1] http://www.fiercebiotech.com/story/spotlight-maxygen-closes-denmark-facility/2007-11-27?utm_medium=rss&utm_source=rss
[2] http://www.fiercebiotech.com/press-releases/press-release-maxygen-licenses-dengue-vaccine-technology-sanofi-pasteur-24-5-m
[3] http://money.cnn.com/news/newsfeeds/articles/apwire/093b24471644dde5201d8bed95ca1812.htm
[4] http://www.fiercebiotech.com/special-reports/4-sanofi-aventis-top-15-r-d-budgets
[5] http://www.fiercebiotech.com/story/new-tech-drives-huge-growth-vaccine-business/2007-10-31
[6] http://www.fiercebioresearcher.com/story/new-approach-to-vaccine-development/2007-01-18
[7] http://www.fiercebiotech.com/story/vaccine-renaissance-attracts-huge-new-venture-investments/2007-05-16
[8] http://www.fiercebiotech.com/story/roche-drops-out-of-dev-deal-with-maxygen/2007-03-14
